ALS therapy

NEURONATA-R inj.is an autologous bone marrow mesenchymal stem cell(autologous BM-MSC) therapy that acts a neuroprotective effect and relieves progression of a disease through prevention of motor nerve cell, survival extension of motor neuron, releasing nerves inflammatory and immune regulation function.
ALS therapy  -

Product Name

NEURONATA-R inj. (autologous BM-MSC)

Pharmaceutical raw materials and their amount

1 Autologous BM-MSC (mainingredient) in Pre-filled syringe (4mL) 4 x 107ea

Autologous cerebrospinal fluid (suspending agent) ………… 4mL

Dosage form and description

(Dosage form) injection type

(Description) cell suspension with ivory color in a colorless transparent syringe

Indications

Amyotrophic lateral sclerosis (ALS: Lou Gehrig's Disease)

Efficacy

Releasing progress of the Amyotrophic lateral sclerosis; ALS (Lou Gehrig’s disease) by using in combination with Riluzole

Dosage

Inject 0.1mL per 1kg of a patient's weight (1.0 × 106 cells) into cerebrospinal Fluid of an ALS patient who has taking Riluzole (100mg / day, orally)

 

Clinical Trials

   -Phase I/II completed

   -Phase III ongoing

   -Route of Administration : Intrathecal Injection

 

As one of efficacy outcomes, the change in the ALSFRS-R score (monthly decline rate) between the lead-in and follow-up period was significantly reduced in the MSC group in comparison to the control group

4 months: 1.10, SE 0.35, 95% CI 0.40 to 1.79, p = 0.003

6 months: 0.92, SE 0.38, 95% CI 0.16 to 1.67, p=0.018).

The results revealed a markedly restrained disease progression in the MSC group that was maintained throughout 6 months.

 

The mechanism of lenzumestrocel on ALS is considered as expression of anti-inflammatory factors, neuroprotective factors and immunoregulation.  When lenzumestrocel was tested in the mouse ALS model, gene expression of Foxp3 was increased, which is the differentiation-inducing transcription factor of Tregs.  In addition to the animal model, in an experiment using peripheral blood cells from healthy persons and ALS patients treated with lenzumestrocel, an increase in Tregs (CD4+, CD25+) was confirmed, along with increased expression of Foxp3 and IL-10.  Based on these findings, lenzumestrocel is considered to show recovery effects on the disease by inhibiting the immune response-initiated apoptosis of neurons through secretion of anti-inflammatory factors that in turn induce an increase in the differentiation of Tregs.